Breaking News Instant updates and real-time market news.

ARLO

Arlo Technologies

$2.84

0.18 (6.77%)

, CCC

Clarivate Analytics

$17.22

0.13 (0.76%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ARLO

Arlo Technologies

$2.84

0.18 (6.77%)

CCC

Clarivate Analytics

$17.22

0.13 (0.76%)

STOK

Stoke Therapeutics

$30.87

1.04 (3.49%)

BMRN

BioMarin

$75.96

0.72 (0.96%)

BIIB

Biogen

$291.50

-2.41 (-0.82%)

AMGN

Amgen

$223.35

2.66 (1.21%)

CTVA

Corteva

$27.06

0.32 (1.20%)

  • 12

    Nov

  • 12

    Nov

  • 07

    Dec

  • 09

    Dec

ARLO Arlo Technologies
$2.84

0.18 (6.77%)

02/06/19
02/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Neutral from Buy at Guggenheim with the firm citing balanced risk/reward. 2. Arlo Technologies (ARLO) downgraded to Underperform from Neutral at BofA/Merrill and to Market Perform from Outperform at Cowen. 3. Celanese (CE) downgraded to Market Perform from Outperform at Cowen with analyst Charles Neivert saying recent subtle changes in industry fundamentals and the macro outlook have made him more cautious. 4. Estee Lauder (EL) downgraded to Hold from Buy at Berenberg with analyst Rosie Edwards saying that while the company's Q2 results were "strong across the board," she expects top-line growth to moderate, due mainly to skincare and Asia-Pacific. 5. Vanda Pharmaceuticals (VNDA) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Charles Duncan saying the company's complaint against the FDA reduces visibility on development timelines for tradipitant in gastroparesis, perhaps even pruritus, and may also affect Hetlioz label expansion efforts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/19
IMPC
02/06/19
NO CHANGE
Target $7.5
IMPC
Outperform
Arlo Technologies price target lowered to $7.50 from $29 at Imperial Capital
Imperial Capital analyst Saliq Khan lowered his price target on Arlo Technologies to $7.50 from $29 citing the company's FY19 revenue guidance of $380M-$420M, which is well below his prior estimate of $591M, and its "disappointing" ongoing operational execution challenges. However, he keeps an Outperform rating on Arlo shares, as he believes the company could see interest from activist investors, strategic buyers or private equity firms.
02/27/19
IMPC
02/27/19
NO CHANGE
Target $7.5
IMPC
Outperform
Arlo Technologies activist likely to obtain board seat, says Imperial Capital
Given VIEX Capital Advisors' history with prior investments and the fund's investment strategy, it is likely for the activist to obtain a board position at Arlo Technologies, Imperial Capital analyst Saliq Khan tells investors in a research note. The analyst earlier this month stated that Arlo's quarterly results and stock performance since could prompt activists to take interest in the company. If Arlo is unsuccessful at improving its financial profile and growth trajectory, VIEX could hold the board accountable and seek representation at the 2019 stockholders meeting, says Khan. He keeps an Outperform rating on Arlo Technologies with a $7.50 price target.
11/11/19
DBAB
11/11/19
INITIATION
Target $4
DBAB
Buy
Arlo Technologies resumed with a Buy at Deutsche Bank
Deutsche Bank resumed coverage of Arlo Technologies with a Buy rating and $4 price target.
CCC Clarivate Analytics
$17.22

0.13 (0.76%)

11/11/19
STFL
11/11/19
INITIATION
Target $18
STFL
Hold
Clarivate Analytics initiated with a Hold at Stifel
Stifel analyst Shlomo Rosenbaum initiated coverage of Clarivate Analytics with a Hold rating and $18 price target. While he likes the company's unique assets and market positioning and sees significant room for operational upside, he also believes the operational improvement over the near-term has been captured by the stock's advance over the year, Rosenbaum tells investors.
07/18/19
07/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sysco (SYY) initiated with an Underweight at Consumer Edge. 2. Sonim (SONM) initiated with a Buy at B. Riley FBR. 3. Ingevity (NGVT) initiated with an Outperform at BMO Capital. 4. Clarivate Analytics (CCC) initiated with a Neutral at Citi. 5. Photronics (PLAB) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/19
SBSH
07/18/19
INITIATION
Target $17
SBSH
Neutral
Clarivate Analytics initiated with a Neutral at Citi (yesterday)
Citi analyst Ashwin Shirvaikar yesterday initiated coverage of Clarivate Analytics with a Neutral rating and $17 price target. The analyst recommends waiting for a better entry point.
05/17/19
RILY
05/17/19
INITIATION
Target $16
RILY
Buy
Clarivate Analytics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Zach Cummins started Clarivate Analytics with a Buy rating and $16 price target.
STOK Stoke Therapeutics
$30.87

1.04 (3.49%)

11/12/19
BTIG
11/12/19
INITIATION
Target $46
BTIG
Buy
Stoke Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated coverage of Stoke Therapeutics with a Buy rating and $46 price target. The analyst cites the potential of the company's technology built by the inventors of SPINRAZA, along with the large informatics engine designed to identify additional disease states that might be treated via modification of pre-mRNA splicing. The "systematic screening methodology called TANGO" has nearly "boundless potential" toward treating a large number of genetic diseases and likely many chronic diseases, Shrader writes in his research note.
07/15/19
COWN
07/15/19
INITIATION
COWN
Outperform
Stoke Therapeutics initiated with an Outperform at Cowen
Cowen analyst Yaron Werber imitated Stoke Therapeutics with an Outperform rating citing its TANGO platform which he said can target multiple indications that have few therapeutic options, allowing it to develop a deep and differentiated pipeline with its first mover advantage.
07/15/19
FBCO
07/15/19
INITIATION
Target $35
FBCO
Outperform
Stoke Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started coverage of Stoke Therapeutics with an Outperform rating and $35 price target. Noting that Stoke's lead asset, STK-001, is in development for Dravet syndrome, the analyst argues that the drug's intuitive mechanism of action and its demonstrated "strong" improvement in survival in a Dravet mouse model supports optimism for the program. Auster expects initial clinical results in 2021 and thinks that, despite the early stage nature of the story, a rapid and meaningful de-risking of the clinical program based on proof-of-concept data from a small number of patients is possible, based on early clinical results, which may lead to significant share appreciation.
10/25/19
HCWC
10/25/19
INITIATION
Target $30
HCWC
Buy
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay initiated coverage of Stoke Therapeutics with a Buy rating and $30 price target. The analyst believes TANGO, an antisense oligonucleotide platform, is an "intriguing approach" at combating haploinsufficiencies.
BMRN BioMarin
$75.96

0.72 (0.96%)

11/12/19
RHCO
11/12/19
INITIATION
Target $110
RHCO
Buy
BioMarin initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of BioMarin with a Buy rating and $110 price target. The analyst cites "several catalysts" for the company over the next 12-18 months, including the phase 3 data on vosoritide by the end of this year, phase 2 data on valrox by mid-2020, and indications of initial uptake for valrox by late 2020-early 2021. Karnauskas adds that her proprietary survey indicates that doctors expect the drug to be used in more patients initially and over time than what the stock currently reflects.
10/28/19
ADAM
10/28/19
NO CHANGE
Target $108
ADAM
Buy
BioMarin price target lowered to $108 from $117 at Canaccord
Canaccord analyst Michelle Gilson lowered her price target on BioMarin to $108 from $117 following Q3 results. The analyst views the shares as undervalued at current levels as the company's long-term strategy of moving toward GAAP profitability through top-line growth begins to come together. Gilson reiterated her Buy rating on BioMarin shares.
10/30/19
SBSH
10/30/19
NO CHANGE
Target $95
SBSH
Buy
BioMarin price target lowered to $95 from $120 at Citi
Citi analyst Mohit Bansal lowered his price target for Biomarin Pharmaceutical to $95 from $120 to account for "slow and steady" launches of Brineura and Palynziq. The analyst believes Valrox and Vosoritide are key to the company's long-term value and he keeps a Buy rating on the shares. He sees the stock trading closer to $85 on good Vosoritide data and $60 on a Vosoritide failure. At the current market price, the Street assigns 50% probability to Vosoritide and 25% to Valrox, Bansal tells investors in a research note.
10/25/19
WEDB
10/25/19
NO CHANGE
Target $152
WEDB
Outperform
BioMarin price target raised to $152 from $128 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for BioMarin to $152 from $128 and maintained an Outperform rating following the company's "strong" Q3 earnings report. In a research note to investors, Moussatos says she anticipates approval for Valrox as "highly likely" based on positive safety and efficacy data to date and projects annual sales could reach over $2B in 2023.
BIIB Biogen
$291.50

-2.41 (-0.82%)

11/12/19
RHCO
11/12/19
INITIATION
Target $337
RHCO
Buy
Biogen initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Biogen with a Buy rating and $337 price target. The analyst is positive on the company's risk-reward profile of its aducanumab gaining FDA approval, with added near-term value from its Spinraza as doctors and patients take time to gain familiarity, durability, and efficacy of newer drugs. Karnauskas sees further upside for Biogen from its interest in the Chinese market for their biosimilars and its capital allocation strategy with Samsung Bioepis.
10/30/19
10/30/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Outperform from Market Perform at Bernstein with analyst Aaron Gal saying that the controversy is solidly around aducanumab. 2. Nu Skin (NUS) upgraded to Hold from Sell at Stifel with analyst Mark Astrachan saying while he thinks trends in China, which makes up 33% of sales, will likely remain negative for the foreseeable future, he now thinks they are unlikely to worsen. 3. Microchip (MCHP) upgraded two notches to Strong Buy from Market Perform at Raymond James while Analog Devices (ADI) was upgraded to Outperform from Market Perform. 4. National Oilwell (NOV) upgraded to Buy from Neutral at Goldman Sachs with analyst Angie Sedita citing the company's revenue growth and cost cutting. 5. AMD (AMD) upgraded to Buy from Hold at Loop Capital and CFRA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/19
BERN
10/30/19
UPGRADE
Target $370
BERN
Outperform
Biogen upgraded to Outperform from Market Perform at Bernstein
Bernstein analyst Aaron Gal upgraded Biogen to Outperform from Market Perform with a $370 price target, saying that the controversy is solidly around aducanumab. Biogen's data was not conclusive, but it was consistent with the science to-date, Gal contends, adding that while the data has gaps, even bears have accepted they at least provide a plausible scientific explanation. The analyst says Biogen's comments, the FDA action and competitors' takes gives him some comfort, and he rejects the notion that Biogen resurrected aducanumab for non-scientific reasons.
11/01/19
STPT
11/01/19
DOWNGRADE
STPT
Hold
Biogen downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Biogen to Hold from Buy.
AMGN Amgen
$223.35

2.66 (1.21%)

11/04/19
MAXM
11/04/19
NO CHANGE
Target $210
MAXM
Buy
BeiGene price target raised to $210 from $170 at Maxim
Maxim analyst Jason McCarthy raised his price target on BeiGene (BGNE) to $210 and kept his Buy rating after it announced a strategic partnership with Amgen (AMGN) last week. The analyst says the deal represents an "endorsement" of BeiGene's potential value while Amgen also gets a "great partner for accessing the China market" along with its unencumbered BTK, PD1 and PARP pipeline approaching commercialization.
11/12/19
RHCO
11/12/19
INITIATION
Target $256
RHCO
Buy
Amgen initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Amgen with a Buy rating and $256 price target. The analyst expects the company's growth rate to recover thanks to its biosimilars business, its ability to develop mid-cycle products, and its interest in the Chinese drug market.
11/05/19
11/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
CANT
11/05/19
UPGRADE
Target $255
CANT
Overweight
Amgen upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young upgraded Amgen to Overweight from Neutral with a price target of $255, up from $230. Recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020, Young tells investors in a research note. In a "potentially volatile election-year macro environment that could leave investors more defensively positioned," Amgen's long-term growth story is beginning to emerge on a fundamental basis, contends the analyst. She sees "significant upside" in the shares over the next 12-18 months with limited downside risk.
CTVA Corteva
$27.06

0.32 (1.20%)

11/01/19
JPMS
11/01/19
DOWNGRADE
Target $27
JPMS
Neutral
Corteva downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Corteva to Neutral from Overweight with a $27 price target.
11/12/19
REDB
11/12/19
INITIATION
REDB
Buy
Corteva initiated with a Buy at Redburn
Redburn initiated coverage of Corteva with a Buy rating.
11/01/19
JPMS
11/01/19
DOWNGRADE
Target $27
JPMS
Neutral
JPMorgan downgrades Corteva to Neutral, cuts target to $27 from $30
JPMorgan analyst Jeffrey Zekauskas downgraded Corteva to Neutral from Overweight with a price target of $27, down from $30. Domestic corn yields are coming in lower in 2019 than in 2018, and may further decrease, but yields have not been sufficiently low to either lift grain prices or seed prices, Zekauskas tells investors in a research note. Further, the analyst says that while Corteva has yet to publish its Q3 cash flow statement, he does not believe that company "has been strongly cash generative year to date."
11/05/19
SPIN
11/05/19
DOWNGRADE
Target $25
SPIN
Hold
Corteva downgraded to Hold from Buy at Spin-Off Research
Spin-Off Research downgraded Corteva to Hold from Buy with a $25 price target.

TODAY'S FREE FLY STORIES

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.